2008
DOI: 10.4161/cc.7.24.7245
|View full text |Cite
|
Sign up to set email alerts
|

Chronic lymphocytic leukemia and treatment resistance in cancer: The role of the p53 pathway

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
56
0
1

Year Published

2011
2011
2019
2019

Publication Types

Select...
6
3

Relationship

1
8

Authors

Journals

citations
Cited by 71 publications
(60 citation statements)
references
References 21 publications
3
56
0
1
Order By: Relevance
“…The tumor suppressor protein p53, often mutated in human tumors, regulates apoptosis and cell survival upon DNA damage (39)(40)(41)(42). Tumor cells with p53 mutations are often resistant to cytotoxic drugs, such as cisplatin (43)(44)(45). Given that PC-3 cells do not express tumor suppressor p53, our data indicate that the cytotoxic effects of PCNA-I1 were likely mediated by both p53-dependent and -independent pathways.…”
Section: Discussionmentioning
confidence: 77%
“…The tumor suppressor protein p53, often mutated in human tumors, regulates apoptosis and cell survival upon DNA damage (39)(40)(41)(42). Tumor cells with p53 mutations are often resistant to cytotoxic drugs, such as cisplatin (43)(44)(45). Given that PC-3 cells do not express tumor suppressor p53, our data indicate that the cytotoxic effects of PCNA-I1 were likely mediated by both p53-dependent and -independent pathways.…”
Section: Discussionmentioning
confidence: 77%
“…Loss of genes encoding p53 or its upstream activator Atm identifies a particularly poor prognosis subset of patients, 39,40 resulting in part from the dependence of conventional cytotoxic agents on the p53 pathway. Clinical trial evidence to date indicates that patients with genetic abnormalities impacting on the p53 pathway need treatment with agents that can act independently of this pathway.…”
Section: Therapeutic Strategies For Cll Patients With a Dysfunctionalmentioning
confidence: 99%
“…Deletions of chromosomes 17p or 11q, the locations of the p53 and ATM genes respectively, identify particularly aggressive forms of the malignancy. 39,40 These deletions are frequently, but not invariably, associated with mutational inactivation of the respective remaining allele, resulting in comprehensive loss of p53-dependent apoptotic responses to DNA-damaging agents. 41,42 A detailed microarray analysis revealed subtle differences in the transcriptional response to DNA damage between CLL cells with lesions in the p53 or ATM genes.…”
Section: Transcriptional Targets Of P53mentioning
confidence: 99%
“…Impaired p53 function through mutation and/or deletion is the best-characterized factor associated with chemoresistance in CLL. 16,17 However, a considerable number (Ͼ 50%) of refractory CLL patients do not exhibit TP53 mutations or 17p deletion. 18 Deregulation of other components of the DNA-damage response and repair pathways might be involved in CLL chemoresistance; for example, ATM, DNA-PK (DNA-dependent protein kinase), the tumor suppressors p16 INK4a and p14 ARF , and microRNA-34a.…”
Section: Introductionmentioning
confidence: 99%